Nebenwirkungen · Tenkasi (previously Orbactiv)
Tenkasi 400 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 7
HOS-131345 · Präparat HOS-097053
Table 3: Frequency of adverse reactions by system organ class System organ class Frequency Adverse Reactions Infections and infestations Common Cellulitis, abscess (limb and subcutaneous) Uncommon Osteomyelitis Blood and lymphatic system disorders Common Anaemia Uncommon Eosinophilia, thrombocytopenia Immune system disorders Uncommon Hypersensitivity (see sections 4.3 and 4.4), anaphylactic reaction Unknown Anaphylactic shock Metabolism and nutrition disorders Uncommon Hypoglycaemia, hyperuricaemia Nervous system disorders Common Headache, dizziness Rare Tremor* Cardiac disorders Common Tachycardia
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-20T11:00:00Z · SHA-256 d20812154b71852f20873c58aef9e7d64a64378ec49b98460d5d2cd5fe13bf59 · Passage 0ca85d5a204debb093e5f0fd9e2f3c236a5b513154b8c41c4e15868b7e71c75c · Zeichen 949–2054 im Abschnitt